Artiva Biotherapeutics (NASDAQ:ARTV) Cut to "Sell" at Wall Street Zen

Key Points

• Wall Street Zen downgraded Artiva Biotherapeutics (NASDAQ:ARTV) from a "hold" to a "sell" rating on Tuesday.
• Analyst sentiment is mixed despite the downgrade — MarketBeat shows an average rating of "Moderate Buy" with a consensus price target of $18.67 (one Strong Buy, three Buy, one Sell).
• ARTV opened at $10.75 with a market cap of $265.7M, recently reported a slight EPS beat (‑$0.84 vs. ‑$0.87 consensus), and is a clinical‑stage developer of allogeneic NK cell CAR therapies for cancer.

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research note issued on Tuesday.

Several other research firms have also recently weighed in on ARTV. Weiss Ratings reiterated a "sell (d-)" rating on shares of Artiva Biotherapeutics in a report on Tuesday, January 27th. Needham & Company LLC restated a "buy" rating and set a $18.00 target price on shares of Artiva Biotherapeutics in a report on Wednesday, March 11th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Artiva Biotherapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $18.67.

Artiva Biotherapeutics Trading Up 4.2%

ARTV stock opened at $10.75 on Tuesday. The stock has a market capitalization of $265.74 million, a price-to-earnings ratio of -3.14 and a beta of 1.46. The firm's 50-day moving average price is $6.87 and its two-hundred day moving average price is $5.04. Artiva Biotherapeutics has a 12-month low of $1.47 and a 12-month high of $14.53.

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last posted its earnings results on Tuesday, March 10th. The company reported ($0.84) earnings per share for the quarter, topping analysts' consensus estimates of ($0.87) by $0.03. Equities analysts predict that Artiva Biotherapeutics will post -3.33 EPS for the current year.

Institutional Trading of Artiva Biotherapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Bank of America Corp DE lifted its position in Artiva Biotherapeutics by 225.8% during the 3rd quarter. Bank of America Corp DE now owns 16,145 shares of the company's stock valued at $46,000 after acquiring an additional 11,190 shares during the period. Prelude Capital Management LLC purchased a new stake in Artiva Biotherapeutics in the third quarter worth about $41,000. OMERS ADMINISTRATION Corp purchased a new stake in Artiva Biotherapeutics in the fourth quarter worth about $91,000. Simplify Asset Management Inc. bought a new position in shares of Artiva Biotherapeutics during the first quarter valued at approximately $150,000. Finally, Bridgeway Capital Management LLC bought a new position in shares of Artiva Biotherapeutics during the second quarter valued at approximately $53,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company's proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva's pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.